Short answer · Medically reviewed summary · Last updated: 2026-04-06
Guillain-Barré Syndrome (GBS) was first clinically characterized in 1916 by French physicians Georges Guillain, Jean Alexandre Barré, and André Strohl, who identified the condition through the observation of elevated protein levels in spinal fluid alongside normal cell counts. The Evolution of Understanding While the 1916 discovery provided the foundational clinical description of Guillain-Barré Syndrome, the medical community initially struggled to distinguish it from other paralytic conditions like polio. Over the 20th century, researchers recognized that Guillain-Barré Syndrome is an immune-mediated disorder where the body’s defenses mistakenly attack the peripheral nerves.
9 people with Guillain-Barre Syndrome have shared their first-person experience on this question at DiseaseMaps.
What is the history of Guillain-Barre Syndrome?
History of Guillain-Barre Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
Guillain-Barré Syndrome (GBS) was first clinically characterized in 1916 by French physicians Georges Guillain, Jean Alexandre Barré, and André Strohl, who identified the condition through the observation of elevated protein levels in spinal fluid alongside normal cell counts.
The Evolution of Understanding
While the 1916 discovery provided the foundational clinical description of Guillain-Barré Syndrome, the medical community initially struggled to distinguish it from other paralytic conditions like polio. Over the 20th century, researchers recognized that Guillain-Barré Syndrome is an immune-mediated disorder where the body’s defenses mistakenly attack the peripheral nerves. This shift from viewing it as a mysterious infection to an autoimmune "post-infectious" phenomenon was a major turning point in neurology.
Milestones in Treatment and Advocacy
Historically, the prognosis for Guillain-Barré Syndrome was grim, with patients often confined to iron lungs for respiratory failure. The development of Intensive Care Unit (ICU) support significantly reduced mortality rates. The 1980s marked a therapeutic revolution with the introduction of plasma exchange (plasmapheresis), followed by the adoption of intravenous immunoglobulin (IVIg) therapy in the 1990s. These treatments drastically improved recovery trajectories, transforming the disease from a frequently fatal outcome to one where many patients achieve significant functional independence.
Modern Perspectives
Today, our understanding of Guillain-Barré Syndrome has been refined by molecular mimicry theory, which explains how certain viral or bacterial infections trigger the immune system to cross-react with nerve components. Advances in genetics and biomarkers now allow clinicians to better differentiate GBS subtypes, such as Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP). Patient advocacy groups have played a vital role in shifting the focus from acute survival to long-term rehabilitation and the management of chronic nerve pain, ensuring that the patient experience remains central to ongoing research.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD)
- Orphanet: The portal for rare diseases and orphan drugs
- GBS/CIDP Foundation International
Posted Sep 3, 2017 by James 2825
Posted Sep 10, 2017 by Connie 2000
Posted Sep 10, 2017 by Debra 2000
Posted Oct 28, 2017 by Kath Donaldson 2065
Posted Sep 8, 2019 by Tara32473 2570
Posted Sep 9, 2019 by Joe Wojtanowski 2500
Posted Jun 19, 2021 by Joseph 600
Posted Sep 10, 2017 by Marta 2000
It was not until 1916 that the neurologists Georges Guillain (1876-1961) and Jean Alexandre Barré (1880-1967) who make the link between these paralysis and abnormalities of the cerebrospinal fluid (lumbar puncture is invented in 1891).
In the years 1930-50 the search for the cause does nothing, the 60s defined the disease of"auto-immune". The 80's identify the anti-body linked to the disease, which is officially called the "Guillain-barré Syndrome".
Posted Oct 19, 2017 by Nicolas 3560
